Mechanism of Action of Thiazolidinediones (TZDs)

Introduction

Thiazolidinediones (TZDs), also known as glitazones, are oral antidiabetic agents used in the management of type 2 diabetes mellitus. The main drugs in this class are pioglitazone and rosiglitazone. Unlike sulfonylureas, TZDs do not stimulate insulin secretion. Instead, they improve insulin sensitivity in peripheral tissues by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor involved in glucose and lipid metabolism.

Mechanism of Action (Step-wise)

1. Thiazolidinediones enter target cells in adipose tissue, skeletal muscle, and the liver.
2. They bind to peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor.
3. Activated PPAR-γ forms a heterodimer with the retinoid X receptor (RXR).
4. The PPAR-γ/RXR complex binds to specific DNA sequences known as PPAR response elements (PPREs).
5. Gene transcription involved in glucose and lipid metabolism is altered.
6. Expression of insulin-sensitive genes increases.
7. Glucose transporter type 4 (GLUT4) expression and activity increase in peripheral tissues.
8. Glucose uptake by skeletal muscle and adipose tissue improves.
9. Insulin resistance decreases significantly.
10. Hepatic glucose production decreases.
11. Circulating free fatty acid concentrations decline.
12. Adiponectin production increases, further enhancing insulin sensitivity.
13. Blood glucose levels decrease without directly stimulating pancreatic insulin secretion.
14. The overall effect is improved insulin sensitivity and better glycemic control in type 2 diabetes mellitus.

A key exam point is that thiazolidinediones activate PPAR-γ, increasing insulin sensitivity in peripheral tissues.

Pharmacokinetics

TZDs are administered orally and are well absorbed from the gastrointestinal tract. They undergo hepatic metabolism, primarily through CYP450 enzymes. Their therapeutic effect develops gradually over several weeks because they act through changes in gene transcription.

Clinical Uses

Thiazolidinediones are used in:

• Type 2 diabetes mellitus
• Combination therapy with metformin
• Combination therapy with sulfonylureas
• Patients with significant insulin resistance

They are not effective in type 1 diabetes mellitus because endogenous insulin is required for their action.

Adverse Effects

Common adverse effects include:

• Weight gain
• Fluid retention
• Peripheral edema
• Increased adipose tissue

Serious adverse effects include:

• Heart failure exacerbation
• Hepatotoxicity (rare)
• Increased fracture risk
• Macular edema

Because of fluid retention, TZDs should be used cautiously in patients with heart failure.

Comparative Analysis

Thiazolidinediones differ from sulfonylureas because they do not stimulate insulin release. Compared with metformin, TZDs primarily improve peripheral insulin sensitivity rather than suppress hepatic gluconeogenesis.

MCQs

1. Thiazolidinediones act by activating:

a) SUR1 receptors
b) PPAR-γ receptors
c) β2 receptors
d) DPP-4 enzymes

Answer: b) PPAR-γ receptors

2. Which drug is a thiazolidinedione?

a) Metformin
b) Pioglitazone
c) Glimepiride
d) Sitagliptin

Answer: b) Pioglitazone

3. PPAR-γ is located primarily in the:

a) Cell membrane
b) Cytoplasm only
c) Nucleus
d) Mitochondria

Answer: c) Nucleus

4. Thiazolidinediones primarily:

a) Increase insulin secretion
b) Improve insulin sensitivity
c) Inhibit glucose absorption
d) Stimulate glucagon release

Answer: b) Improve insulin sensitivity

5. TZDs increase expression of:

a) GLUT4
b) Sodium channels
c) Histamine receptors
d) Dopamine receptors

Answer: a) GLUT4

6. A major therapeutic effect is:

a) Reduced insulin resistance
b) Increased ketogenesis
c) Increased glucagon secretion
d) Reduced renal filtration

Answer: a) Reduced insulin resistance

7. TZDs are used primarily in:

a) Type 1 diabetes mellitus
b) Type 2 diabetes mellitus
c) Diabetes insipidus
d) Gestational diabetes only

Answer: b) Type 2 diabetes mellitus

8. A common adverse effect is:

a) Weight gain
b) Hypoglycemia
c) Hypernatremia
d) Bradycardia

Answer: a) Weight gain

9. TZDs may worsen:

a) Heart failure
b) Asthma
c) Hyperthyroidism
d) Peptic ulcer disease

Answer: a) Heart failure

10. Thiazolidinediones increase production of:

a) Adiponectin
b) Histamine
c) Thyroxine
d) Cortisol

Answer: a) Adiponectin

11. The glucose-lowering effect of TZDs develops:

a) Immediately within minutes
b) Within hours only
c) Gradually over weeks
d) Only after insulin injection

Answer: c) Gradually over weeks

12. Compared with sulfonylureas, TZDs:

a) Have a higher hypoglycemia risk
b) Directly stimulate insulin release
c) Primarily improve insulin sensitivity
d) Block potassium channels

Answer: c) Primarily improve insulin sensitivity

FAQs

What is the mechanism of action of thiazolidinediones?

Thiazolidinediones activate PPAR-γ receptors, improving insulin sensitivity in adipose tissue, muscle, and liver.

Do TZDs stimulate insulin secretion?

No. They improve tissue responsiveness to insulin rather than increasing insulin release.

Why do TZDs take several weeks to work?

Because their effects depend on alterations in gene transcription and protein expression.

What are common side effects of TZDs?

Weight gain, fluid retention, and peripheral edema.

Why are TZDs avoided in heart failure?

Because they can cause fluid retention and worsen congestive heart failure.

How do TZDs differ from metformin?

TZDs mainly improve insulin sensitivity, whereas metformin primarily reduces hepatic glucose production.

References

Goodman & Gilman’s The Pharmacological Basis of Therapeutics
https://accessmedicine.mhmedical.com/book.aspx?bookid=3191

Katzung’s Basic and Clinical Pharmacology
https://accessmedicine.mhmedical.com/content.aspx?bookid=3382

Tripathi KD. Essentials of Medical Pharmacology
https://www.jaypeedigital.com

Harrison’s Principles of Internal Medicine
https://accessmedicine.mhmedical.com

Download